Skip to main content

Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.

Publication ,  Journal Article
Kauffman, CA; Pappas, PG; McKinsey, DS; Greenfield, RA; Perfect, JR; Cloud, GA; Thomas, CJ; Dismukes, WE
Published in: Clin Infect Dis
January 1996

Thirty patients with documented sporotrichosis were treated with 200-800 mg of fluconazole daily. Fourteen patients had lymphocutaneous infection; only five (36%) of these patients had any underlying illnesses. Sixteen patients had osteoarticular or visceral sporotrichosis; 12 (75%) of these patients had underlying diseases, mostly alcoholism, diabetes mellitus, and chronic obstructive pulmonary disease. Eleven of the 30 patients had relapsed after prior antifungal therapy. Most patients were treated with 400 mg of fluconazole; however, four received 200 mg of fluconazole daily for the entire course, and four received 800 mg of fluconazole daily for a portion of their therapy or for the entire course of therapy. Fluconazole therapy cured 10 (71%) of 14 patients with lymphocutaneous sporotrichosis. However, only five (31%) of 16 patients with osteoarticular or visceral sporotrichosis responded to therapy; the conditions of two of these five patients improved only, and there was no documented cure of their infections. With the exception of alopecia in five patients, toxic effects were minimal. Fluconazole is only modestly effective for treatment of sporotrichosis and should be considered second-line therapy for the occasional patient who is unable to take itraconazole.

Duke Scholars

Published In

Clin Infect Dis

DOI

ISSN

1058-4838

Publication Date

January 1996

Volume

22

Issue

1

Start / End Page

46 / 50

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sporotrichosis
  • Middle Aged
  • Microbiology
  • Male
  • Humans
  • Fluconazole
  • Female
  • Dose-Response Relationship, Drug
  • Antifungal Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kauffman, C. A., Pappas, P. G., McKinsey, D. S., Greenfield, R. A., Perfect, J. R., Cloud, G. A., … Dismukes, W. E. (1996). Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis, 22(1), 46–50. https://doi.org/10.1093/clinids/22.1.46
Kauffman, C. A., P. G. Pappas, D. S. McKinsey, R. A. Greenfield, J. R. Perfect, G. A. Cloud, C. J. Thomas, and W. E. Dismukes. “Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.Clin Infect Dis 22, no. 1 (January 1996): 46–50. https://doi.org/10.1093/clinids/22.1.46.
Kauffman CA, Pappas PG, McKinsey DS, Greenfield RA, Perfect JR, Cloud GA, et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis. 1996 Jan;22(1):46–50.
Kauffman, C. A., et al. “Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.Clin Infect Dis, vol. 22, no. 1, Jan. 1996, pp. 46–50. Pubmed, doi:10.1093/clinids/22.1.46.
Kauffman CA, Pappas PG, McKinsey DS, Greenfield RA, Perfect JR, Cloud GA, Thomas CJ, Dismukes WE. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis. 1996 Jan;22(1):46–50.

Published In

Clin Infect Dis

DOI

ISSN

1058-4838

Publication Date

January 1996

Volume

22

Issue

1

Start / End Page

46 / 50

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Sporotrichosis
  • Middle Aged
  • Microbiology
  • Male
  • Humans
  • Fluconazole
  • Female
  • Dose-Response Relationship, Drug
  • Antifungal Agents